Some stocks are sort of like the late comedian Rodney Dangerfield; they "don't get no respect." Others get some respect, but not the respect they probably deserve. Their market valuations just don't reflect their full potential.

We asked three Motley Fool contributors to point out some of those underrated stocks that they think are smart picks to buy in April. Here's why they chose Axsome Therapeutics (NASDAQ: AXSM), Johnson & Johnson (NYSE: JNJ), and Pfizer (NYSE: PFE) as opportunities that especially stand out.

Prosper Junior Bakiny (Axsome Therapeutics): Last year, Axsome Therapeutics' share price doubled, partly due to the FDA approving its depression medicine Auvelity for use. But 2023 isn't shaping up to be great for the biotech, at least so far. The company's stock is down by 19% since the start of the year.

Continue reading

Source Fool.com